Two PD-1 checkpoint inhibitors in oncology

Nivolumab vs pembrolizumab: trial pipelines compared

A side-by-side view of the nivolumab and pembrolizumab clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for nivolumab and 16+ for pembrolizumab. Add up to three more drugs to widen the comparison.

nivolumab (16) vs pembrolizumab (16)22 active2015–2032

Hide completed

nivolumabpembrolizumab

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingCompletedTerminatedUnknown status

'15

'17

'19

'21

'23

'25

'27

'29

'31

nivolumab

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerP2

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)P2

INITIATEP2

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)P3

ATHENAP3

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsP2

Nivolumab With Chemotherapy in Pleural Mesothelioma After SurgeryP2

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabP2

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsP3

NIVOPTIMIZEP4

PICASSOP2

ctDNA Lung RCTP2

DIALP2

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerP2

reICBP2

CANIQOLP4

pembrolizumab

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerP2

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)P3

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%P2

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyP3

MITO 27P2

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )P2

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)P3

KEYNOTE-C11P2

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerP2

DIALP2

TroFuse-007P3

STELLAR-305P2

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaP2

Krascendo 2P3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerP3

Chrono-EVPP3

Upcoming readouts

9 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Head to head

Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.

nivolumab (Opdivo)Immuno-oncology checkpoint inhibitors

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Mar 2027

Next phase 3 readout

pembrolizumab (Keytruda)Immuno-oncology checkpoint inhibitors

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Jan 2028

Next phase 3 readout

Key trials across both drugs

Top 16 registered phase 2–4 trials across nivolumab and pembrolizumab, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

Drug	Trial	Title	Phase	Status	Primary completion
nivolumab	NCT07028125	CANIQOL: Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivoluma…	Phase 4	Recruiting	Oct 2028
nivolumab	NCT06116461	NIVOPTIMIZE: Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response	Phase 4	Unknown	Oct 2024
pembrolizumab	NCT06170788	TroFuse-007: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone i…	Phase 3	Recruiting	Jan 2028
pembrolizumab	NCT06793215	Krascendo 2: A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab a…	Phase 3	Recruiting	Nov 2028
pembrolizumab	NCT07222566	Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination …	Phase 3	Recruiting	Feb 2029
nivolumab	NCT03522246	ATHENA: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment F…	Phase 3	Active, not recruiting	May 2024
pembrolizumab	NCT04895358	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2…	Phase 3	Active, not recruiting	Apr 2026
nivolumab	NCT04444921	EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Ca…	Phase 3	Active, not recruiting	Mar 2027
pembrolizumab	NCT07346053	Chrono-EVP: The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advan…	Phase 3	Not yet recruiting	Dec 2030
nivolumab	NCT03117049	Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)	Phase 3	Completed	Feb 2020
pembrolizumab	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na…	Phase 3	Completed	Jun 2022
pembrolizumab	NCT04889118	Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as…	Phase 3	Completed	Jan 2023
nivolumab	NCT05255302	DIAL: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Di…	Phase 2	Recruiting	May 2025
pembrolizumab	NCT05255302	DIAL: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Di…	Phase 2	Recruiting	May 2025
nivolumab	NCT07130032	reICB: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic…	Phase 2	Recruiting	Aug 2025
nivolumab	NCT04966663	ctDNA Lung RCT: Using ctDNA to Determine Therapies for Lung Cancer	Phase 2	Recruiting	Aug 2026

Track nivolumab and pembrolizumab with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track both drugs

FAQ

How do the nivolumab and pembrolizumab clinical pipelines compare?: ClinicalTrials.gov currently lists 16+ phase 2–4 trials for nivolumab and 16+ for pembrolizumab. The timeline above plots both side by side and refreshes daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
Can I add more drugs to the comparison?: Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.

Upcoming readouts

Head to head

Key trials across both drugs

Track nivolumab and pembrolizumab with ComplyRx

Individual pipelines and other comparisons

FAQ

Be the first to access ComplyRx